This is an example CRF used to collect general concomitant medications in a study. This CRF was designed to allow the sponsor to use either CMENRF or CMENRTPT to represent an intervention was ongoing.
CMCAT
Hidden/pre-populated
GENERAL
Indicate if the subject used any Nicotine patches . If Yes, include the appropriate details where indicated on the CRF.
Were any Nicotine patches used?
CMOCCURNot Submitted
<NY codelist>
If collected on the CRF, sponsor may insert instructions to ensure each record has a unique identifier.
CMSPID
_________________
Record only one treatment per line. Provide the full trade or proprietary name of the medication/treatment; otherwise, record the generic name .
CMTRT
_________________
Record the reason the medication was taken based on clinical investigator's evaluation. If taken to treat a condition, and a diagnosis was made, the indication should be the diagnosis. If taken to treat a condition, and no diagnosis was made, the indication should be the signs and symptoms. If taken as prophylaxis, report as "Prophylaxis for " and include a description of the condition(s).
CMINDC
_________________
Record the dose of medication/treatment per administration (e.g., 200).
CMDSTXTCMDOSTXT/ CMDOSE
_________________
Record the dose unit of the dose of concomitant medication/treatment taken (e.g., mg).
Unit
CMDOSU
<UNIT codelist>
Record the pharmaceutical dosage form (e.g., TABLET CAPSULE, SYRUP) of delivery for the concomitant [medication/treatment/therapy] taken.
Dose Form
CMDOSFRM
<FRM codelist>
Record how often the medication was taken (e.g., BID, PRN).
Frequency
CMDOSFRQ
<FREQ codelist>
Provide the route of administration for the medication.
Route
CMROUTE
<ROUTE codelist>
Record the date the concomitant medication/treatment was first taken using this format (DD-MON-YYYY). If the subject has been taking the concomitant medication/treatment for a considerable amount of time prior to the start of the study, it is acceptable to have an incomplete date. Concomitant medications taken during the study are expected to have a complete start date. Prior concomitant medications that are exclusionary should have both a start date and an end date.
CMSTDATCMSTDTC
_ _ / _ _ _ / _ _ _ _
Record the concomitant medication/treatment as ongoing if the subject has not stopped taking the concomitant medication/treatment at the time of data collection and the end date should be left blank.
Is the medication ongoing?
CMONGOCMENRF or CMENRTPT
<NY codelist>
Record the date the concomitant medication/treatment was stopped using this format (DD-MON-YYYY). If the subject has not stopped taking the concomitant medication/treatment leave this field blank.
CMENDATCMENDTC
_ _ / _ _ _ / _ _ _ _
Order
CDASH Variable
Question Text
Prompt
CRF Completion Instructions
Type
SDTMIG Target
SDTMIG Target Mapping
Controlled Terminology Code List Name
Permissible Values
Pre-Populated Value
Query Display
List Style
Hidden
1
CMCAT
What is the category for the medication?
Concomitant Medication Category
Record the medication category, if not pre-printed on the CRF.
Text
CMCAT
GENERAL
Yes
2
CMOCCUR
Were any Nicotine patches used?
Any Nicotine patches Used?
Indicate if the subject used any Nicotine patches . If Yes, include the appropriate details where indicated on the CRF.
Text
N/A
(NY)
Yes; No
3
CMSPID
What is the medication identifier?
CM Number
If collected on the CRF, sponsor may insert instructions to ensure each record has a unique identifier.
Text
CMSPID
prompt
4
CMTRT
What was the medication?
Concomitant Medication
Record only one treatment per line. Provide the full trade or proprietary name of the medication/treatment; otherwise, record the generic name .
Text
CMTRT
6
CMINDC
For what indication was the medication taken?
Indication
Record the reason the medication was taken based on clinical investigator's evaluation. If taken to treat a condition, and a diagnosis was made, the indication should be the diagnosis. If taken to treat a condition, and no diagnosis was made, the indication should be the signs and symptoms. If taken as prophylaxis, report as "Prophylaxis for " and include a description of the condition(s).
Text
CMINDC
7
CMDSTXT
What was the individual dose of the medication?
Dose
Record the dose of medication/treatment per administration (e.g., 200).
Text
CMDOSTXT; CMDOSE
CMDOSTXT/ CMDOSE
prompt
8
CMDOSU
What is the unit?
Unit
Record the dose unit of the dose of concomitant medication/treatment taken (e.g., mg).
Text
CMDOSU
(UNIT)
CAPSULE; g; IU; mg; mL; PUFF; TABLET; ug
prompt
9
CMDOSFRM
What was the dose form of the medication?
Dose Form
Record the pharmaceutical dosage form (e.g., TABLET CAPSULE, SYRUP) of delivery for the concomitant [medication/treatment/therapy] taken.
Record the date the concomitant medication/treatment was first taken using this format (DD-MON-YYYY). If the subject has been taking the concomitant medication/treatment for a considerable amount of time prior to the start of the study, it is acceptable to have an incomplete date. Concomitant medications taken during the study are expected to have a complete start date. Prior concomitant medications that are exclusionary should have both a start date and an end date.
Date
CMSTDTC
prompt
13
CMONGO
Is the medication ongoing?
Ongoing
Record the concomitant medication/treatment as ongoing if the subject has not stopped taking the concomitant medication/treatment at the time of data collection and the end date should be left blank.
Text
CMENRF; CMENRTPT
CMENRF or CMENRTPT
(NY)
Yes
checkbox
14
CMENDAT
What was the end date?
End Date
Record the date the concomitant medication/treatment was stopped using this format (DD-MON-YYYY). If the subject has not stopped taking the concomitant medication/treatment leave this field blank.
Date
CMENDTC
prompt
This is the SDTM dataset associated with the above example CRF. This SDTM dataset used CMENRF to represent ongoing interventions. More information can be found in SDTMIGSection 4.4.7,Use of Relative Timing Variables.The sponsor include CMDECOD. The sponsor is required to provide the dictionary name and version in the Define-XML document.
Rows 1-6:
The subject reported each instance of aspirin use. The frequency of each instance is represented in CMDOSFRQ and is ONCE.
Rows 7-9:
The subject reports the use of 3 medications. Diovan and Zoloft were still being taken by the subject, Astelin was a nasal spray where 2 sprays were taken twice a day in each nostril. Note that only partial start dates are provided for Diovan and Zoloft.
Row 10:
The subject took aspirin with a frequency of "PRN". This approach assumes that knowing exactly when aspirin was used is not important for evaluating safety and efficacy in this study.